Pharmsynthez boosts board

pharmafile | October 12, 2010 | Appointment | Manufacturing and Production, Research and Development Pharmsynthez, appointment, manufacturing and production, research and development 

Moscow-based pharmaceutical company JSC Pharmsynthez has appointed Miroslav Ravic and Howard Fisher to its board as independent non-executive directors.

Miroslav Ravic is a member of the British Pharmacological Society, the American Society of Clinical Pharmacology and Therapeutics and the American Society of Clinical Oncology.

He will have board oversight of the Pharmsynthez’s international clinical research programme, which the company hopes will produce drugs that can be launched simultaneously in the CIS, EU and US markets.

Meanwhile, Howard is president and founder of New York-based consulting company HSF Business Advisors and he will oversee various international projects. These include Pharmsynthez’s planned expansion to overseas markets and potential acquisition of pharmaceutical and research companies in the EU, Israel and the US.

Pharmsynthez’s chief executive and chairman Dmitry Genkin said: “The appointment of non-executive directors will further enhance our governance structure ahead of our planned IPO later this year.

Moreover, the addition to our board of such distinguished and respected pharmaceutical industry experts such as Miroslav Ravic and Howard Fisher will be of tremendous support to our international expansion.”

The Russian pharmaceutical company focuses on the research, manufacture and distribution of pharmaceuticals and active pharmaceutical ingredients (APIs).

Related Content

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

funk

Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content